InvestorsHub Logo
Followers 21
Posts 1676
Boards Moderated 0
Alias Born 07/09/2005

Re: None

Thursday, 02/18/2021 3:25:50 PM

Thursday, February 18, 2021 3:25:50 PM

Post# of 149
Two fairly good PR`s the past couple of days and stock sells off 20% alone today. Bought some trading shares close to lows as the selling stopped at the 1 year 200 day SMA which sits at $16.12.

Also today Piper 'encouraged' by Immunic datasets for IMU-838
After Immunic filed "an in-depth 8K" with a detailed analysis of the Phase 2 CALVID-1 and Phase 2 PSC studies of IMU-838, Piper Sandler analyst Yasmeen Rahimi said she is "encouraged by both datasets," adding that the topline data from the Phase 2 proof-of-concept study for IMU-838 in 11 primary sclerosing cholangitis, or PSC, "strong." The analyst, who continues to see multiple sclerosis and ulcerative colitis as Immunic's "key value drivers," also said she views COVID-19 and PSC as "call optionalities." Rahimi keeps an Overweight rating and $71 price target on Immunic shares.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IMUX News